Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Aleksandra Aitullina"'
Publikováno v:
Medicina, Vol 55, Iss 2, p 33 (2019)
Background and objectives: Colistin is used for the treatment of multidrug-resistant (MDR) Gram-negative bacteria infection in critically ill patients. It is recommended to adjust the dose in cases of renal impairment but not in cases of augmented re
Externí odkaz:
https://doaj.org/article/d9c92e7b9d7e4b1183eb5b090e1591d2
Autor:
Eva Strīķe, Inga Mauliņa, Angelika Krūmiņa, Dace Bandere, Aleksandra Aitullina, Katrīna Bandere, Roberts Erts
Publikováno v:
Proceedings of the Latvian Academy of Sciences. Section B, Natural Sciences, Vol 75, Iss 1, Pp 40-46 (2021)
There have been a limited number of studies in Latvia that were focused on vancomycin therapeutic drug monitoring (TDM), especially during the initiation phase of the therapy. The aim of this study was to investigate details of vancomycin therapy in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eba0278bd8c96d4108e6bc08cd722137
https://doaj.org/article/7ab3b9eda0354531a28fe7d65f707cc6
https://doaj.org/article/7ab3b9eda0354531a28fe7d65f707cc6
Publikováno v:
International Journal of Clinical Pharmacy. 43:509-517
Background Colistin is a potentially nephrotoxic antibiotic used for the management of multidrug-resistant bacterial infections in critically ill patients. Co-administration with other nephrotoxins was reported as a potentially modifiable risk factor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1bd0dfec4df9131f9cd3ba245be3ef13
https://doi.org/10.1007/s11096-020-01154-6
https://doi.org/10.1007/s11096-020-01154-6
Publikováno v:
British journal of clinical pharmacologyREFERENCES. 88(5)
Acute neutropenia induced by antibiotics is a rare side effect of this frequently prescribed class of drugs. We aim to find similarities and differences between reported cases.Through a database search (PubMed, 1968-2020), we identified published cas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f0ff65daaeed5b85c39077ae09301d65
https://pubmed.ncbi.nlm.nih.gov/34897762
https://pubmed.ncbi.nlm.nih.gov/34897762
Publikováno v:
Proceedings of the Latvian Academy of Sciences. Section B, Natural Sciences, Vol 72, Iss 4, Pp 201-206 (2018)
Colistin is used systemically in critically ill patients for treatment of infections caused by multi-drug resistant (MDR) Gram-negative bacteria, e.g., Acinetobacter baumanii. It is potentially nephro- and neurotoxic. It is recommended to decrease th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::06f458915bb07037305b3422ba436e80
https://doaj.org/article/3342f602ba324f61a6d06b0fc938ccf8
https://doaj.org/article/3342f602ba324f61a6d06b0fc938ccf8
Autor:
Inga Mauliņa, Angelika Krūmiņa, Aleksandra Aitullina, Renārs Erts, Katrīna Bandere, Dace Bandere, Eva Strīķe
Publikováno v:
Proceedings of the Latvian Academy of Sciences. Section B. Natural, Exact, and Applied Sciences.. 75:238-238
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bbe97df8ab29e8e8da4c1982c95d35c3
https://doi.org/10.2478/prolas-2021-0035
https://doi.org/10.2478/prolas-2021-0035
Publikováno v:
Medicina; Volume 55; Issue 2; Pages: 33
Medicina
Volume 55
Issue 2
Medicina, Vol 55, Iss 2, p 33 (2019)
Medicina
Volume 55
Issue 2
Medicina, Vol 55, Iss 2, p 33 (2019)
Background and objectives: Colistin is used for the treatment of multidrug-resistant (MDR) Gram-negative bacteria infection in critically ill patients. It is recommended to adjust the dose in cases of renal impairment but not in cases of augmented re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::43487a52f8b88694eefa228316e5fb2f
https://doi.org/10.3390/medicina55020033
https://doi.org/10.3390/medicina55020033
Publikováno v:
Journal of Young Pharmacists. 5:18-21
Clopidogrel ineffectiveness is a serious problem in antiplatelet therapy. Many factors may contribute to this phenomenon. One of them is clopidogrel drug-drug interaction with CYP2C19 and CYP3A4 enzyme inhibitors. The main goal of this descriptive st
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ddcffa89ac4d09ebf96eb7eb13625695
https://doi.org/10.1016/j.jyp.2013.01.002
https://doi.org/10.1016/j.jyp.2013.01.002